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Editorial
Potential Fiscal Consequences of Universal
Screening for Group-B Streptococci
The proposed recommendation for extensive screening for group-B streptococci (GBS)
during pregnancy published in the Federal Registe? and advocated by the American
Academy of Pediatrics will have an impact on health-care economics to varying
extents in at least 2 areas. Implementation of the pending mandate for universal
screening will 1) require direct funding to expand the current proactive prenatal
infectious-disease screening and 2) indirectly fuel the fiscal consequences of failure.
The cost efficiency of universal screening for GBS vs. situationally dictated prophy-
laxis has been approximated. The CDC cited the analysis of Stray-Pederson in
indicating that the cost per case prevention was <$35,000. The aggregate studies of
Boyer and Gotoff as well as that of Strickland et al. and Yancey and Duff similarly
support this contention. Based on the high cost of caring for neonates with early-onset
disease ($22,000-33,800), the policy of screening and treatment has been projected to
be economically justified. 1’6
Gibbs et al. reviewed the 2-year experience of a universal screening program with
strict application of criteria and found the compliance rate in administering indicated
prophylaxis with a complex algorithm to be only 80.3%. The incidence ofGBS sepsis
in the last year’s protocol was 0.5 per 1,000 live births. Of the 5 cases of early-onset
neonatal GBS, 4 were due to a failure to identify GBS with the initial screening
culture. All 3 ofthe 4 cases were said to be protocol violations attributed to nonselective
media. The majority of hospital laboratories do not use selective media in screening
for GBS. The reason is simply that, because of the additional steps required to process
a specimen for GBS, the use ofselected media markedly increases the cost of culturing.
Had selective broth media been used, there is no absolute guarantee that the cultures
would have been positive for GBS.
The recommendations for universal screening as advocated by the American Acad-
emy of Pediatrics are predicated upon the desire to bring the number of cases of
early- and late-onsetGBS neonatal disease to zero. The proposal for universal screening
deviates significantly from the prior recommendations of Minkoff and Mead and the
more formal policy advocated in 1992 by the American College of Obstetricians and
Gynecologists (ACOG). What would be the difference in terms of serious residual
sequelae or death as a result of GBS neonatal disease between universal culturing
and selective prophylaxis vs. selective prophylaxis? The projected numbers are ex-
ceedingly small, and the difference in cost is significant.
In June 1996, the ACOG Committee on Obstetric Practicel published a positional
paper dealing with the prevention of early-onset GBS disease in newborns. Noting
that there were no, nor were there likely to be, clinical studies comparing the efficiency
of the strategies using antepartum culture and selected intrapartum prophylaxis with
intrapartum prophylaxis based on clinical risk factors, the committee recommended
that obstetric providers adopt of 2 strategies for the prevention of early-onset GBS
disease in the newborns: a strategy based on late prenatal culture (35-37 weeks) as
the primary risk determinant or a strategy based solely on clinical risk factor. If the
culture-based strategy is used, intrapartum antibiotic prophylaxis needs to be extended
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TABLE I. Funding of proactive infectious disease screening
Funding sources
Organism Medicare NE state HMO Blue Cross/Blue Shield For-profit hospital
Neisseria gonorrhoeae DNA probe
and Chlamydia trichomais
(87178) $14.67 $23.62 $30.80 $12.00 $30.00
Asymptomatic bacteriuria (87086) $11.26 $11.91 $22.00 $24.00 $21.00
Treponema pallidum (VDRL/FTA)
(86781) $7.67 $7.67 __b $12.00 $33.95
HBV (86289) $17.06 $17.45 $17.60 b $21.25
HCV (86302 and 86303) $20.20 RNE $18.70 __b $32.00
HIV-I/HIV-2 (8631 I) $8.67 $27.46 $14.30 $20.00 $22.00
Rubella (86762) $20.30 $21.37 __b __b $16.00
GBS (8295 I) $18.22 $20.04 $32.00 $32.00 $21.00
M. tuberculosis (86585 and 86580) Not listed $7.15 $11.00 $21.00
Total $ 118.05 $129.52 $142.55 $ 1.00 $218.20
aVDRL venereal disease research laboratory test; FTA fluorescent treponemal antibody testing; HBV hepatitis B virus; HCV hepatitis C virus;
HIV-I/2 human immunodeficiency virus types and 2; GBS group B streptococcus. Numbers in parentheses refer to billing codes.
bFunded within the global prenatal fee.
to all women who have positive cultures. Irrespective of which strategy is chosen,
neither will prevent all early-onset GBS disease.
If you spend health-care dollars, you have to be sure the recipient receives the
maximum value for the money. To save infant, others may have to be compromised.
A small incremental reduction in the incidence ofGBS neonatal disease can probably
be achieved over prophylactic therapy of high-risk categories, but at what price? The
cost of screening and serial monitoring of GBS carriers and their sexual consorts will
take dollars from the health-care system which may be better spend proactively on
other aspects of in utero medicine, such as surveillance for hepatitis C virus, Mycobacte-
um tuberculosis, or vaginal bacteriosis.
DIRECT FISCAL CONSEQUENCES
The infectious organisms currently screened for within the context of prenatal care
are listed in Table 1; however, not all of these are funded by add-on health-care
dollars. The proposed mandate for universal or comprehensive screening brings up
the ugly question, "Who is going to pay for serial screening of gravidas with GBS?"
Screening entails at least 2 culture sites (Vaginal and rectal) and, in some situations,
2 maternal sets of cultures. Is the cost of proactive health care of infectious-disease
surveillance to grow or are tests to be deleted from proactive health care to accommo-
date GBS testing? Do we have the fiscal resources to do everything? Hopefully, the
anser is "yes." Historically, health-maintenance organizations (HMOs) and the Federal
Government pay greater lip service than actual implementation of cost for health
care maintenance.
INDIRECT FISCAL CONSEQUENCES
Irrespective of whether a policy of universal screening, selective high-risk category
screening, or prophylactic high-risk categories therapy is implemented, a rare case of
GBS will occur. The implied assumption that zero occurrence will be the consequence
of universal screening will make ensuing cases of early-onset GBS disease a medical
or legal nightmare. In a realistic sense, one has to try to imagine a family practitioner
in a rural setting who had adhered to this proactive health-care mandate and failed.
Under cross examination concerning a prior negative maternal culture, the physician
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would be asked to answer questions such as, "What quality controls are in place at
the testing facilities? Were the cultures properly taken? Was selective media used?
How many sites were individually sampled? Were the cultures properly handled in
transport? Were all appropriate culture sites tested?" Anything short ofa Lexis response
to these types of questions could result in a 7-figure judgment.
A DIFFERENT PERSPECTIVE
A plea for financial prudence should not be the essence of policy. The real problem
with universal screening is that it was developed with a myopic focus. Early-onset
disease caused by GBS is a major component within a larger problem, namely perinatal
septicemia. Perinatal septicemia is defined as sepsis within the first 24-36 h of life.1
The factors which select for perinatal septicemia are markedly different from those
responses for neonatal septicemia. The Enterobacteriaeae are as important as GBS
as the etiologic agent for serious sepsis in the first 24-36 h of life. The preventative
measures for GBS should equally address the need to circumvent neonatal disease
caused by the Enterobacteriaceae. The classic case of perinatal Enterobacteriaceae
septicemia is a neonate born to a gravida who experiences prolonged rupture of the
fetal membrane (ROM) or preterm labor and ROM. Nonprophylaxis or prophylaxis
with just penicillin in a gra;eida with prolonged ROM or preterm labor because of
the absence ofGBS in the vaginal or rectal bacterial flora leaves this group at significant
risk for perinatal septicemia due to, e.g., Enterobacteriaceae or Hemophilias influenzae.
11
A policy to aggressively cirumvent the tragic morbidity and mortality due to early-
onset GBS needs to be formulated, but its methodology must be global, not myopic.
Gilles R.G. Monif MD
Director of Infectious DiseasesmOB/GYN
Creighton University School ofMedicine
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